The dual SGLT1/2 inhibitor sotagliflozin was also tested in a dedicated HF trial (SOLOIST-WHF) [19]; however, exclusively, patients with T2DM and recent hospitalization for worsening HF were enrolled. Here, SLC5A1 is linked to type 2 diabetes mellitus.